Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foreign Trials, U.S. Liability: Pfizer Dealt Setback As Solicitor General Asks Supreme Court Not To Review Nigerians' Trovan Suit

This article was originally published in PharmAsia News

Executive Summary

The Solicitor General has advised the U.S. Supreme Court not to grant Pfizer's petition to review a case alleging the company did not provide adequate informed consent in testing its antibiotic Trovan in Nigerian children

You may also be interested in...



Out Of Africa: Why A Court Decision On Trovan Affects Pharma

Last month, a federal appeals panel jolted Pfizer by ruling that dozens of Nigerians can sue the drugmaker in a U.S. court over its handling of a 1996 clinical trial for its Trovan (trovafloxacin mesylate) antibiotic

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel